Table des Matières
Publicité
387158--G_GA_Lumax540_mul.book Page 9 Friday, February 1, 2013 5:38 PM
Follow-up with BIOTRONIK Home Monitoring
Monitoring using the Home Monitoring function does not serve to replace regular
in-office appointments with the physician required for other medical reasons.
Follow-up supported by Home Monitoring can be used to functionally replace in-office
follow-up under the following conditions:
• The patient was informed that the physician must be contacted if symptoms worsen
or if new symptoms arise despite use of the Home Monitoring function.
• Device messages are transmitted regularly.
• The physician decides whether the data transmitted via Home Monitoring with
regard to the patient's clinical condition as well as the technical state of the device
system are sufficient. If not, an in-office follow-up has to be carried out.
Possible early detection due to information gained via Home Monitoring may necessi-
tate an additional in-office follow-up. For example, the data may indicate at an early
stage lead problems or a foreseeable end of service time (ERI). Furthermore the data
could provide indications of previously unrecognized arrhythmias or modification of the
therapy by reprogramming the device.
Follow-up with the programmer
Use the following procedure for in-office follow-up:
1
Record and evaluate the external ECG.
2
Check the sensing and pacing functions.
3
Interrogate the device.
4
Evaluate the status and automatically measured follow-up data.
5
Possibly evaluate statistics and Holter/IEGM recording.
6
Manually perform standard tests if necessary.
7
Possibly customize program functions and parameters.
8
Transmit the program permanently to the device.
9
Print and document follow-up data (print report).
10 Finish the follow-up for this patient.
Note for physicians
Use the patient ID card to obtain information on magnet behavior and tachyarrhythmia
detection.
en • English
All manuals and user guides at all-guides.com
®
W WARNING
Possible loss of left ventricular pacing if the pacing threshold has been determined
exclusively by ATM
The pacing threshold determined by ATM should not be used directly to determine the
left ventricular pacing amplitude (LV). The effectiveness of the LV pacing amplitude
has to be confirmed.
Notes for patients
A patient brochure and a patient ID card are supplied with the device.
• Provide the patient with the patient brochure and patient ID card.
•
Draw the patient's attention to prohibitory signs:
places with prohibitory signs must be avoided.
Replacement Indication
Foreword
The battery level can be continuously monitored with Home Monitoring and checked
during follow-ups.
Possible battery levels
• BOL: Beginning of Life (i.e. BOS: Beginning of Service): 70% charge
• MOL 1: Middle of Life : 70% to 40% residual charge
• MOL 2: Middle of Life : 40% residual charge
• ERI: Elective Replacement Indication, (i.e. RRT: Recommended Replacement Time)
• EOS: End of Service
ERI
The device can monitor the cardiac rhythm for at least 3 months and deliver at least six
maximum energy shocks until EOS.
The selected parameters in the device program do not change.
W CAUTION
Temporally limited therapy
When the ERI display is noticed for the first time during a follow-up, the remaining
service time can be much less than 3 months even if follow-ups have been performed
at three month intervals.
9
Publicité
Table des Matières
